Shohei Komatsu

Kobe University Graduate School of Medicine

H指数:21

被引数:1,714

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to “Methodological Concerns on the Optimal Timing of Adjuvant S-1 After Pancreatectomy”

对“关于胰腺切除术后辅助S-1治疗最佳时机的‘方法学问题’”的回应

Journal of Hepato-Biliary-Pancreatic Sciences

IF2.8

2026-09-210

PRE

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

不可切除性肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后出血事件的临床特征、预测因素及抗血栓治疗的影响

Hepatology Research

IF3.4

2026-04-210

PRE

Fujimasa Tada; Atsushi Hiraoka; Hideko Ohama; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Yoshihide Ueda; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Jumpei Okamura; Hideyuki Tamai; Shinichiro Nakamura; Yoshiko Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Kazunari Tanaka; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Shohei Komatsu; Takumi Fukumoto; Takanori Matsuura; Soo Ki Kim; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada; the Real-life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

肝内肿瘤负荷对接受阿替利珠单抗联合贝伐珠单抗治疗的合并肝外转移的肝细胞癌患者预后的影响

Hepatology Research

IF3.4

2026-04-100

PRE

Kazunari Tanaka; Kunihiko Tsuji; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Yoshihide Ueda; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Jumpei Okamura; Hideyuki Tamai; Shinichiro Nakamura; Yoshiko Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Fujimasa Tada; Hideko Ohama; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Shohei Komatsu; Takumi Fukumoto; Takanori Matsuura; Soo Ki Kim; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada; the Real-Life Practice Experts for HCC (RELPEC) Study Group and Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group

Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

淋巴细胞-单核细胞比值预测接受度鲁单单抗联合曲美单抗治疗的HCC患者的生存情况

Liver International

IF5.2

2026-02-260

PRE

Tomomitsu Matono; Toshifumi Tada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Takashi Nishimura; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Hideyuki Tamai; Shohei Komatsu; Takanori Matsuura; Yoshihide Ueda; Soo Ki Kim; Hideko Ohama; Fujimasa Tada; Shinichiro Nakamura; Yoshiko Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Shinya Fukunishi; Kazunari Tanaka; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Jumpei Okamura; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada; the RELPEC Group and HCC 48 Group

Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors

肝内病灶对接受仑伐替尼或免疫检查点抑制剂治疗的肝细胞癌患者病灶特异性应答率的影响

HPB

IF2.4

2025-11-150

PRE

Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy

肝切除术后复发性肝细胞癌中肿瘤可切除标准的实用性

HEPATOLOGY RESEARCH

IF3.4

2025-11-010

Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma

多学科策略包括局部治疗，旨在实现阿替利珠单抗联合贝伐珠单抗治疗后肝细胞癌患者的无药状态。

ONCOLOGY LETTERS

IF2.2

2025-10-010

Assessment of surgical difficulty in multiple laparoscopic liver resection using the aggregate value of scores based on the IWATE criteria

基于IWATE标准评分总和值的多发腹腔镜肝切除术手术难度评估

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

IF2.7

2025-10-010

PRE

Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis

度鲁特玛联合特瑞普利单抗在合并门静脉血栓和高肿瘤负荷的肝细胞癌患者中的有效性与安全性：一项多中心回顾性分析

Hepatology Research

IF3.4

2025-09-060

PRE

Hatanaka, Takeshi; Yata, Yutaka; Hiraoka, Atsushi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Kakizaki, Satoru; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Toyoda, Hidenori; Koshiyama, Yuichi; Ogawa, Chikara; Nishikawa, Hiroki; Nishimura, Takashi; Kawata, Kazuhito; Kosaka, Hisashi; Matsui, Kosuke; Naganuma, Atsushi; Tanaka, Hironori; Ohama, Hideko; Kuroda, Hidekatsu; Matono, Tomomitsu; Aoki, Tomoko; Ochi, Hironori; Imai, Michitaka; Nakamura, Shinichiro; Komatsu, Shohei; Tamai, Hideyuki; Okamura, Jumpei; Kanayama, Yuki; Tanaka, Kazunari; Tada, Fujimasa; Yoshida, Osamu; Nouso, Kazuhiro; Morishita, Asahiro; Tsutsui, Akemi; Nagano, Takuya; Itokawa, Norio; Okubo, Tomomi; Arai, Taeang; Matsuura, Takanori; Noritake, Hidenao; Enomoto, Hirayuki; Kaibori, Masaki; Fukumoto, Takumi; Hiasa, Yoichi; Kudo, Masatoshi; Kumada, Takashi

Exploring the potential utility of modified difficulty scores based on the IWATE criteria for assessing the surgical difficulty of laparoscopic repeat liver resection

基于IWATE标准探索修改后难度评分在评估腹腔镜重复肝切除术手术难度方面的潜在应用价值

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES

IF2.7

2025-09-010

PRE

Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study

动脉接触胰腺癌切除术后的局部复发率降低的学习曲线效应：一项单中心回顾性研究

ANNALS OF GASTROENTEROLOGICAL SURGERY

IF3.3

2025-09-010

OAAI

Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma

格瑞特营养风险指数作为不可切除肝癌患者接受度伐利尤单抗联合特瑞普利单抗治疗期间免疫介导不良反应的风险因素的潜在作用

Journal of Gastroenterology

IF5.5

2025-08-200

PRE

Hideko Ohama; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Hideyuki Tamai; Shohei Komatsu; Fujimasa Tada; Shinichiro Nakamura; Yoshiko Nakamura; Teruki Miyake; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Kazunari Tanaka; Takanori Matsuura; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

达鲁瓦鲁单抗联合特雷美鲁单抗在不可切除肝细胞癌老年患者中的安全性与有效性：一项多中心分析

Hepatology Research

IF3.4

2025-08-060

PRE

Tomomitsu Matono; Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Hiroki Nishikawa; Kazunari Tanaka; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Yuichi Koshiyama; Hidenori Toyoda; Chikara Ogawa; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Hidenao Noritake; Hideko Ohama; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Takashi Nishimura; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Tomoko Aoki; Hidekatsu Kuroda; Yutaka Yata; Hideyuki Tamai; Takanori Matsuura; Shohei Komatsu; Yoshihide Ueda; Yoshiko Nakamura; Osamu Yoshida; Kosuke Matsui; Shinichiro Nakamura; Hirayuki Enomoto; Masaki Kaibori; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; the Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group

Prognostic Significance of GLIM-Defined Malnutrition in Patients With Resectable Pancreatic Adenocarcinoma Following Upfront Surgery

可切除胰腺腺癌患者行 upfront 手术后 GLIM-定义营养不良的预后意义

Annals of Gastroenterological Surgery

IF3.3

2025-06-300

OAAI

Impact of a dilated main pancreatic duct in the expected remnant pancreas on the incidence of clinically significant remnant pancreatic lesion after resection of noninvasive and microinvasive intraductal papillary mucinous neoplasms

扩大的主胰管对非侵袭性和微侵袭性导管内乳头状黏液性肿瘤切除术后残留胰腺发生临床显著残留病变发生率的影响

Pancreatology

IF2.7

2025-04-050

PRE